1. 1002TiPBAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib with continuous schedule vs cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer. (23rd October 2018) Authors: Colombo, N; Nicoletto, O; Benedetti Panici, P; Tognon, G; Lissoni, A A; Bologna, A; Tomao, F; Fossati, R; Tettamanzi, F; Rulli, E; Galli, F; Alvisi, M F; Torri, V; Biagioli, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 191PD_PR9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio. (23rd October 2018) Authors: Conte, P F; Guarneri, V; Bisagni, G; Piacentini, F; Brandes, A A; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Frassoldati, A; Musolino, A; Garrone, O; Taverniti, C; Rimanti, A; Sarti, S; Rubino, D; Bologna, A; Vicini, R; Balduzzi, S; D'Amico, R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A novel sphygmomanometer for central venous pressure assessment during stress echocardiography. (4th February 2022) Authors: Campagnano, E; Ciampi, Q; Bortolani, B; Cercenelli, L; Lodi, S; Marcelli, E; Bologna, A; Bombardini, T; Villari, B; Picano, E Journal: European heart journal Issue: Volume 23(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Issue 2 (February 2021) Authors: Pignata, Sandro; Lorusso, Domenica; Joly, Florence; Gallo, Ciro; Colombo, Nicoletta; Sessa, Cristiana; Bamias, Aristotelis; Salutari, Vanda; Selle, Frédèric; Frezzini, Simona; De Giorgi, Ugo; Pautier, Patricia; Bologna, Alessandra; Orditura, Michele; Dubot, Coraline; Gadducci, Angiolo; Mammoliti,... Journal: Lancet oncology Issue: Volume 22:Issue 2(2021) Page Start: 267 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy. (18th December 2017) Authors: Friedlander, M; Rau, J; Lee, C K; Meier, W; Lesoin, A; Kim, J -W; Poveda, A; Buck, M; Scambia, G; Shimada, M; Hilpert, F; King, M T; Debruyne, P; Bologna, A; Malander, S; Monk, B J; Petru, E; Calvert, P; Herzog, T J; Barrett, C Journal: Annals of oncology Issue: Volume 29:Number 3(2018) Page Start: 737 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer. (16th February 2018) Authors: Piccirillo, M C; Scambia, G; Bologna, A; Signoriello, S; Vergote, I; Baumann, K; Lorusso, D; Murgia, V; Sorio, R; Ferrandina, G; Sacco, C; Cormio, G; Breda, E; Cinieri, S; Natale, D; Mangili, G; Pisano, C; Cecere, S C; Di Napoli, M; Salutari, V Journal: Annals of oncology Issue: Volume 29:Number 5(2018) Page Start: 1189 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗